ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
114.06
0.00
(0.00%)
Closed July 15 4:00PM
0.00
0.00
(0.00%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
114.06
Bid
114.01
Ask
115.15
Volume
-
0.00 Day's Range 0.00
74.75 52 Week Range 142.00
Market Cap
Previous Close
114.06
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
2,750,790
Shares Outstanding
397,683,837
Dividend Yield
-
PE Ratio
83.77
Earnings Per Share (EPS)
1.36
Revenue
3.62B
Net Profit
541.5M

About DexCom Inc

DexCom Inc designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver. DexCom Inc designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
DexCom Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DXCM. The last closing price for DexCom was $114.06. Over the last year, DexCom shares have traded in a share price range of $ 74.75 to $ 142.00.

DexCom currently has 397,683,837 shares outstanding. The market capitalization of DexCom is $45.36 billion. DexCom has a price to earnings ratio (PE ratio) of 83.77.

DexCom (DXCM) Options Flow Summary

Overall Flow

Bearish

Net Premium

-495k

Calls / Puts

133.33%

Buys / Sells

40.00%

OTM / ITM

250.00%

Sweeps Ratio

0.00%

DXCM Latest News

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call...

Dexcom Expands AID Partnership Into The Netherlands

The world’s most connected continuous glucose monitoring system‡, Dexcom G6, now connects with the Omnipod® 5 Automated Insulin Delivery (AID) System in The Netherlands. DexCom, Inc. (Nasdaq:...

Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes

Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA conference presentations reiterate the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.560.493392070485113.5115.34109.421882167112.02684615CS
4-1.12-0.972391040111115.18117.91108.712793794113.44371764CS
12-17.12-13.0507699344131.18138.92108.712750790120.90434786CS
26-9.53-7.71097985274123.59142108.712895909124.60133275CS
52-22.64-16.5618141917136.714274.753556716111.57707694CS
156-322.66-73.882579227436.72659.451867.112366542143.91943205CS
260-35.66-23.817793214149.72659.451867.111821978183.90244006CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0

DXCM Discussion

View Posts
oilin07 oilin07 4 months ago
Why is nobody talking about $TRIB. Trinity Biotech recently purchased DexCom Incs technology. $TRIB is a hidden gem
👍️0
DollarSquad DollarSquad 3 years ago
https://www.webcaster4.com/Player/Index?webcastId=41975&g=5ff46fae-ca0b-4696-b3a4-4a64d6dfc159&uid=3737459&sid=
👍️0
akamaii akamaii 3 years ago
I will
👍️0
DollarSquad DollarSquad 3 years ago
You think sens will disrupt, check out KNWN. They have not only a breakthrough platform for numerous non-invasive medical applications but the 60+ patents to secure their success.
👍️0
ranchhand71 ranchhand71 3 years ago
SuperBowl commercial will reach huge multi million viewer audience to both educate about CGM, make Dexcom better known to potential audience and is part of "direct to consumer" or significantly ramped up DTC marketing program in preparation for the launch of G7 device later this year. If you check the job websites like LinkedIn,Indeed and monster.com you can see that huge hiring ramp of over 150 spots to increase manufacturing shifts in Arizona, add more detail teams to call on pharmacies and support additional future R&D efforts. The 12 months 8/21 to 8/22 are going to be explosive IMHO.
👍️0
zagdad zagdad 4 years ago
Get in below a buck? Yep I'd love to do that but......maybe another stock?
👍️0
ranchhand71 ranchhand71 4 years ago
Upcoming presentation at update at JPMorgan Healthcare Conference may be a catalyst
👍️0
akamaii akamaii 4 years ago
I think it’s bc sens will disrupt that sector superior product 6 month product that is superior period. If you missed dxcm get in sens cause it makes cents to be in here below a buck
👍️0
whytestocks whytestocks 4 years ago
BREAKING NEWS: $DXCM Why Is No One Talking About DexCom Stock?

Glucose monitor maker DexCom (NASDAQ: DXCM) has had a rough month. After a Wall Street analyst downgraded the stock Oct. 2 and sharply trimmed its price target, the price fell over the next 30 days, with the majority of the downward movement taking place in the last week of Octo...

Got this from DXCM - Why Is No One Talking About DexCom Stock?
👍️0
whytestocks whytestocks 4 years ago
Just In: $DXCM Why I Just Bought These 2 Under-the-Radar Stocks

Last week, I bought shares of Dexcom (NASDAQ: DXCM) and Inari Medical (NASDAQ: NARI) . But while it's obvious to me that Dexcom is an incredibly successful stock, having run up almost 3,400% since its IPO 15 years ago, it still hasn't garnered a lot of investor attention. ...

Got this from DXCM - Why I Just Bought These 2 Under-the-Radar Stocks
👍️0
ranchhand71 ranchhand71 4 years ago
what was reason for Wells Fargo analyst downgrade today?
👍️0
zagdad zagdad 4 years ago
Hmmm, probably whether you got in at $50 or $500 might influence you feelings these days... Great company, product, and big PPS.
👍️0
Trueheart Trueheart 4 years ago
The share price is supposed to go up.

I want a refund on my investment!

Trueheart
👍️0
Trueheart Trueheart 4 years ago
CNBC's Joshua Brown discussed DXCM today. He said it was priced high but given the need for its products he blessed it, along with other companies that produce medical devices. He mentioned Japan, Europe and America as being great markets.

He was asked if the stock was too high and his reply was it had a long runway and wouldn't bet against it.

Zounds!

Truehea
👍️0
Trueheart Trueheart 4 years ago
The beauty of DexCom is that it's growing because Americans are growing --- in size.

Diabetes is rampant and fat people continue to eat and seem not to give a damn that the disease is killing them slowly.

Onward and upward!

Trueheart
👍️0
whytestocks whytestocks 4 years ago
News: $DXCM Could DexCom Be a Millionaire-Maker Stock?

Winners tend to keep on winning. And make no mistake about it:  DexCom (NASDAQ: DXCM) is a winner. During its 21 years in business, the medical-device maker has transformed how individuals manage diabetes. DexCom's market cap now stands at close to $40 billion. The company generated nea...

Got this from DXCM - Could DexCom Be a Millionaire-Maker Stock?
👍️0
conix conix 4 years ago
Motley Fool just recommended DXCM today.
👍️0
ranchhand71 ranchhand71 5 years ago
Not too big to avoid strategic acquisition by a Lilly or Johnson & Johnson
👍️0
zagdad zagdad 5 years ago
Wow, another 30% up. A winner that keeps on producing.
👍️0
zagdad zagdad 5 years ago
Great day here today...must be good news coming.
👍️0
YMYBH YMYBH 5 years ago
👍️0
YMYBH YMYBH 5 years ago
Nmrd has just recieved CE mark for sugar beat device , non invasive wireless CMG
👍️0
harry crumb harry crumb 5 years ago
Bought into this at 60 way back an still holding it. Hoping for split, never know peeps, $$$$$ patience
👍️0
north40000 north40000 5 years ago
AAC, in New Orleans this coming weekend, has as one of its featured breakthrough presentations "the Apple Watch". We own DXCM shares here too, as well as AAPL shares.
👍️0
dicer666 dicer666 5 years ago

I use their G6 and it is great product. Their customer service is one of the worst ever. Now, they are outsourcing it overseas where they know nothing about it? Geez.
👍️0
zagdad zagdad 6 years ago
Wow, outstanding Q and prospects for the rest of the year and beyond!
👍️0
legalizeMJ legalizeMJ 6 years ago
DXCM: Normal for diabetics.

https://www.webmd.com/diabetes/guide/normal-blood-sugar-levels-chart-adults
👍️0
zagdad zagdad 6 years ago
Just keeps climbing- nice
👍️0
T695 T695 6 years ago
Short
👍️0
T695 T695 6 years ago
Short
👍️0
zagdad zagdad 6 years ago
Great news for both the company and the world of diabetics!
👍️0
north40000 north40000 6 years ago
DXCM: The reason:

http://ih.advfn.com/p.php?pid=nmona&article=77048172
👍️0
zagdad zagdad 6 years ago
Moving north very nicely....looking good!
👍️0
wiltonio wiltonio 7 years ago
HENDERSON GROUP PLC has filed a new 13G, reporting 10.2% ownership in $DXCM - https://fintel.io/i/henderson-group and https://fintel.io/i/henderson-group
👍️0
wplee757 wplee757 7 years ago
fillin the gap..
👍️0
TREND1 TREND1 7 years ago
DXCM RSI 5


👍️0
TREND1 TREND1 7 years ago
DXCM RSI 5

👍️0
zagdad zagdad 8 years ago
....and now this ...

Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equipment"...

zagdad
👍️0
zagdad zagdad 8 years ago
Huge news for DexCom, its shareholders, and the patients in need IMHO.

zagdad
👍️0
north40000 north40000 8 years ago
http://finance.yahoo.com/news/fda-approval-dexcom-non-adjunctive-210100548.html
👍️0
TREND1 TREND1 8 years ago
NO MEDICARE COVERAGE YET.
👍️0
TREND1 TREND1 8 years ago
DXCM DAY


👍️0
TREND1 TREND1 8 years ago

As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place of standard daily finger-stick blood testing.

Dexcom wants regulatory approval so that the information gathered by the device from a patient could be used to administer insulin without the standard fingerstick-based blood reading. If approved by the agency, analysts have said Dexcom could eventually garner Medicare coverage and grow the use of its device by as much as 23%.

The Clinical Chemistry and Clinical Toxicology Devices Panel, which met Thursday, voted 8-2 to support that there is reasonable assurance that the G5 Mobile CGM system is safe for the proposed indications for use.

It voted 9-1 that there is reasonable assurance that the device is effective for the proposed indications for use, and in an 8-2 vote, supported the benefits of the G5 Mobile CGM system outweighed the risks for the proposed indications for use.

"This recommendation is a big milestone for people with diabetes," Kevin Sayer, DexCom’s president and CEO, said in a statement, “We commend the FDA for bringing this important subject into a public forum, and thank the panel members, as well as the public speakers for their willingness to participate.”

Still, there was some concern before going into the panel review. Those concerns centered on the heavy reliance of data from computer simulation studies and the limitations of the human factor studies conducted by Dexcom, according to a review by Jefferies, a securities firm that rates Dexcom shares a buy.

Additional discussion at the review focused on how a majority of CGM patients already make dosing decisions based on information gathered by the devices and there might need to be appropriate training, which is only possible by a labeled indication. It was suggested by the panel that training instructions be detailed on the label itself.

Perhaps one of the key takeaways is that the regulatory agency and Dexcom remain in discussions about a post-marketing study design, which will have to be locked down before final FDA approval is granted. Wall Street analysts believe the final decision on that study could establish a clinical standard that all other devicemakers will need to meet if they want to secure a dosing claim for their own CGMs.
👍️0
TREND1 TREND1 8 years ago
Dexcom management will hold a conference call to discuss the meeting starting at 8:30 a.m. (Eastern Time) on Friday, July 22 2016.

To listen to the conference call, please dial (888) 771-4371 (US/Canada) or (847) 585-4405 (International) and use the confirmation number "430 195 42" approximately five minutes prior to the start time.

The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to “Our Company,” then “Investor Relations,” and then “Events and Webcasts,” and will be archived there for future reference
👍️0
TREND1 TREND1 8 years ago
DexCom Inc. (DXCM) Halted due to pending news

July 21,
2016 07:00 AM ET
Dow Jones Newswires
👍️0
$Pistol Pete$ $Pistol Pete$ 8 years ago
$DXCM Daily and Weekly Ichimoku Chart




👍️0
zagdad zagdad 8 years ago
DXCM - what's going on here today? Anybody a close follower?

Thx, zagdad
👍️0
ramad ramad 9 years ago
echo pharmaceuticals on the fringe of non invasive CGM for diabetes. This could be a major break through which would hurt DXCM future growth. I do not know the particulars but their is a big buzz that they are near the clinical testing stage. How is it that DXCM has not developed a non invasive CGM system. If I was a diabetic I wouldn't want to prick my finger or draw blood on a daily bases. Does anyone have any insight regarding DXCM having a non invasive CGM or on Echo thereapeutics.
👍️0
TREND1 TREND1 9 years ago
DXCM Conference Call

Management will hold a conference call as previously scheduled on November 4, 2015 starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at www.dexcom.com by navigating to "Our Company," then "Investor Relations," and then "Events and Webcasts," and will be archived for future reference. To listen to the conference call, please dial (888) 771-4371 (US/Canada) or (847) 585-4405 (International) and use the confirmation number "40455195" approximately five minutes prior to the start time.
👍️0
magness magness 9 years ago
8% revenue beat and bullish comments make DXCM very enticing at these prices.
👍️0

Your Recent History

Delayed Upgrade Clock